Role of new potential immune blocking molecules in the development and progression of hepatocellular carcinoma
10.3969/j.issn.1001-5256.2023.04.031
- VernacularTitle:新兴免疫阻断分子在肝细胞癌发生发展中的作用
- Author:
Ying TAO
1
,
2
;
Zhangxiu LIAO
1
Author Information
1. School of Pharmacy, Youjiang Medical University for Nationalities, Bose, Guangxi 533000, China
2. School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Bose, Guangxi 533000, China
- Publication Type:Review
- Keywords:
Carcinoma, Hepatocellular;
Immunosuppressive Agents;
Molecular Targeted Therapy
- From:
Journal of Clinical Hepatology
2023;39(4):948-955
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors around the world. The emergence of immune checkpoint inhibitors targeting programmed death-1/programmed death-ligand 1 and cytotoxic T lymphocyte-associated antigen-4 has brought great breakthroughs in the treatment of HCC. However, since HCC is a type of tumor with high heterogeneity, monotherapy is only effective for a small number of patients and may not be able to achieve long-lasting benefits due to drug resistance, and therefore, it is necessary to explore the potential of new immune checkpoint inhibitors in the prevention and treatment of HCC. This article analyzes and summarizes the biological characteristics of the new immune checkpoints T cell immunoglobulin and ITIM domain (TIGIT), V-domain immunoglobulin suppressor of T-cell activation (VISTA), B and T lymphocyte attenuator (BTLA), and B7 homologous protein-4 (B7-H4) and their expression and function in HCC. The analysis shows that TIGIT, VISTA, BTLA, and B7-H4 are highly expressed in HCC tissue and are associated with the prognosis of HCC patients, and targeted blocking of corresponding pathways can effectively inhibit the progression of HCC, suggesting that these molecules are potential targets for tumor treatment and that in-depth studies can provide new directions for HCC immunotherapy.
